@ckosmidis.bsky.social
New publication in JAC-AMR📄
We describe successful treatment of chronic pulmonary aspergillosis using once-weekly rezafungin delivered via OPAT, alongside a health economic assessment suggesting advantages over daily echinocandins.
🔗 academic.oup.com/jacamr/artic...
@aspergillosis.bsky.social
We describe successful treatment of chronic pulmonary aspergillosis using once-weekly rezafungin delivered via OPAT, alongside a health economic assessment suggesting advantages over daily echinocandins.
🔗 academic.oup.com/jacamr/artic...
@aspergillosis.bsky.social
Successful outpatient parenteral antimicrobial therapy with rezafungin for chronic pulmonary aspergillosis: a case report and health economic assessment
AbstractBackground. Chronic pulmonary aspergillosis (CPA) is a serious lung disorder caused by Aspergillus fungal infection with high morbidity and mortali
academic.oup.com
December 23, 2025 at 7:12 AM
New publication in JAC-AMR📄
We describe successful treatment of chronic pulmonary aspergillosis using once-weekly rezafungin delivered via OPAT, alongside a health economic assessment suggesting advantages over daily echinocandins.
🔗 academic.oup.com/jacamr/artic...
@aspergillosis.bsky.social
We describe successful treatment of chronic pulmonary aspergillosis using once-weekly rezafungin delivered via OPAT, alongside a health economic assessment suggesting advantages over daily echinocandins.
🔗 academic.oup.com/jacamr/artic...
@aspergillosis.bsky.social